FindTrial
Sign In

Study on the prognostic significance of ARHGEF26 in PTEN - deficient glioblastoma

Study on the prognostic significance of ARHGEF26 in PTEN - deficient glioblastoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100047854
Enrollment
Unknown
Registered
2021-06-27
Start date
2021-07-15
Completion date
Unknown
Last updated
2022-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

glioblastoma

Interventions

glioblastoma samples group:none

Sponsors

The First Affiliated Hospital of Army Medical University, PLA
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Clinical diagnosis was PTEN wild-type GBM,PTEN mutant GBM,H3K27M(+)GBM and GBM.

Exclusion criteria

Exclusion criteria: No.

Design outcomes

Primary

MeasureTime frame
ARHGEF26 expression;PTENexpression;—

Countries

China

Contacts

Public ContactYao Xiaohong

The First Affiliated Hospital of Army Medical University, PLA

yxh15@163.com+86 15923566825

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026